{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"48.66","value":"136.17"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"6"}],"units":"Participants"}],"description":"Blood samples were collected at indicated time points for pharmacokinetic analysis of belantamab mafodotin. PK parameters were analyzed using standard non-compartmental analysis. AUC\\[0-t\\] was calculated using the linear trapezoidal rule for each incremental trapezoid and the log trapezoidal rule for each decremental trapezoid.","dispersionType":"Geometric Coefficient of Variation","groups":[{"description":"Participants with relapsed/refractory multiple myeloma (RRMM) were administered with 2.5 milligram per kilogram (mg/kg) belantamab mafodotin intravenous (IV) infusion over 30-60 minutes on day 1 of each 21-days cycle. Participants were treated until disease progression, intolerable toxicity, end of study or informed consent withdrawal.","id":"OG000","title":"Belantamab Mafodotin"}],"paramType":"GEOMETRIC_MEAN","populationDescription":"Pharmacokinetic (PK) population","reportingStatus":"POSTED","timeFrame":"Pre-dose (within 30 minutes prior to start of infusion), end of infusion (EOI), 2, 4, 8 and 24 hours post start of infusion (HPS) on Day 1, anytime on Day 2, 4, 8, 15 and 22 of Cycle 1 (each cycle is of 21 days)","title":"AUC[0-t] of Belantamab Mafodotin Cys- Monomethyl Auristatin-F (Cys-mcMMAF)","type":"SECONDARY","unitOfMeasure":"Hours*nanograms per milliliter (h*ng/mL)"}